These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15195321)

  • 21. Mumps vaccine virus strains and aseptic meningitis.
    Bonnet MC; Dutta A; Weinberger C; Plotkin SA
    Vaccine; 2006 Nov; 24(49-50):7037-45. PubMed ID: 16884835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurologic disorders after measles-mumps-rubella vaccination.
    Mäkelä A; Nuorti JP; Peltola H
    Pediatrics; 2002 Nov; 110(5):957-63. PubMed ID: 12415036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MMR mass vaccination campaigns, vaccine-related adverse events, and the limits of the decision making process, in Brazil.
    Cunha SC; Dourado I
    Health Policy; 2004 Mar; 67(3):323-8. PubMed ID: 15036819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Annual trends in adverse events following mumps vaccination in Japan: A retrospective study.
    Ohfuji S; Tanaka T; Nakano T; Kase T; Kondo K; Fukushima W; Hirota Y
    Vaccine; 2022 Feb; 40(7):988-993. PubMed ID: 35058077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety evaluation of MMR vaccine during a primary school campaign in Saudi Arabia.
    Al-Mazrou Y; Tumsah S; Khalil M; Al-Jeffri M; Afzal MA; al-Ghamdy Y; Mishkhas A; Essa M
    J Trop Pediatr; 2002 Dec; 48(6):354-8. PubMed ID: 12521278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
    Bernsen RM; van der Wouden JC
    Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measles-mumps-rubella vaccination and asthma-like disease in early childhood.
    Hviid A; Melbye M
    Am J Epidemiol; 2008 Dec; 168(11):1277-83. PubMed ID: 18845551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of age on the incidence of aseptic meningitis following immunization with monovalent mumps vaccine.
    Muta H; Nagai T; Ito Y; Ihara T; Nakayama T
    Vaccine; 2015 Nov; 33(45):6049-53. PubMed ID: 26431987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tutorial in biostatistics: the self-controlled case series method.
    Whitaker HJ; Farrington CP; Spiessens B; Musonda P
    Stat Med; 2006 May; 25(10):1768-97. PubMed ID: 16220518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.